Review
Oncology
Yong Li, Xian Chen, Wenzhu Li, Yongsong Ye, Xiaohua Du, Shaodan Sun, Lirong Liu, Haibo Zhang
Summary: This study reported a successful case of treating mCRC patient with cetuximab in combination with fruquintinib after resistance to chemotherapy, showing good response. The mechanisms of this combination therapy and other clinical research on combined treatments were discussed, highlighting the potential benefits of combining small-molecule anti-vascular drugs with anti-EGFR in CRC treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Benny Vittrup Jensen, Jakob Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen
Summary: This study investigated the use of cetuximab and irinotecan in third-line treatment for mCRC patients, regardless of RAS or BRAF mutation status, and achieved certain efficacy. Shortening the treatment time while maintaining good treatment outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Shigenori Kadowaki, Toshiki Masuishi, Takashi Ura, Keiji Sugiyama, Seiichiro Mitani, Yukiya Narita, Hiroya Taniguchi, Kei Muro
Summary: The study evaluated the safety of FOLFOXIRI plus cetuximab in Japanese patients with RAS wild-type mCRC, and found that the combination therapy had acceptable safety profile and promising anti-tumor activity, supporting further research in this patient population.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Gunnar Folprecht, Erika Martinelli, Thibault Mazard, Dominik P. Modest, Akihito Tsuji, Regina Esser, Chiara Cremolini, Alfredo Falcone
Summary: Triplet chemotherapy regimens in combination with anti-EGFR agents or bevacizumab are recommended standard treatments for unresectable mCRC. While the dosing schedule of FOLFOXIRI with bevacizumab is established, the optimal dosing with anti-EGFR agents is still unknown. Clinical trials have shown improved survival and response rates with FOLFOXIRI, alone or combined with bevacizumab, for mCRC patients, and promising results with anti-EGFR agents.
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
Matthew Fowler, Helene Tobback, Alice Karuri, Paz Fernandez-Ortega
Summary: Encorafenib, a BRAF inhibitor, in combination with cetuximab, an EGFR inhibitor, has been approved for the treatment of BRAF(V600E)-mutant metastatic colorectal cancer. Nurses play a crucial role in managing the care of these patients, including early identification and management of treatment-related adverse events, as well as educating patients and caregivers about these events.
SUPPORTIVE CARE IN CANCER
(2023)
Editorial Material
Oncology
Miriam Ferrer, Tobias Janowitz
Summary: This study found that low-intensity exercise can improve tumor control and response to immunotherapy in an orthotopic pancreatic cancer model, and combination therapy significantly reduces tumor growth.
Article
Oncology
Chwee Ming Lim, Anthony Liou, Michelle Poon, Liang Piu Koh, Lip Kun Tan, Kwok Seng Loh, Bengt Fredrik Petersson, Eric Ting, Dario Campana, Boon Cher Goh, Noriko Shimasaki
Summary: The study demonstrated that combining cetuximab with autologous expanded NK cells in patients with recurrent and/or metastatic NPC is safe and showed promising clinical responses, with some patients achieving durable stable disease.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary Middleton, Wenfeng Chen, Regina Esser, Johannes Nippgen, Howard Burris
Summary: The study investigated the efficacy of cetuximab plus irinotecan in RAS-wild-type metastatic colorectal cancer patients as second-line treatment, showing improvements in progression-free survival, objective response rate, and quality of life. Additionally, almost half of patients in the irinotecan arm received poststudy cetuximab therapy.
Article
Oncology
Kun-Han Lee, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yee Chao, Hao-Wei Teng
Summary: Metastatic middle/low rectal cancer shows lower efficacy in anti-EGFR treatment compared to left-sided colon cancer, both in terms of progression-free survival, overall survival, and overall response rates for both first-line and non-first-line treatment. TCGA analysis reveals genetic heterogeneity in rectal tumors, showing shared features with both left- and right-sided colon cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo
Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.
Article
Oncology
Stefano Mariani, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Clelia Donisi, Mara Persano, Giovanna Pinna, Erika Cimbro, Alissa Parrino, Dario Spanu, Andrea Pretta, Eleonora Lai, Nicole Liscia, Alessio Lupi, Enrica Giglio, Grazia Palomba, Milena Casula, Marina Pisano, Giuseppe Palmieri, Mario Scartozzi
Summary: This study investigated the efficacy of liquid biopsy-driven cetuximab rechallenge in a selected population of CRC patients with RAS and BRAF WT. The results showed that liquid biopsy-driven cetuximab rechallenge was effective and consistent with previous phase II studies. In addition to molecular selection, a longer anti-EGFR free interval was confirmed as an important predictor for this therapeutic option.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Chiara Nicolazzo, Valentina Magri, Luca Marino, Francesca Belardinilli, Federica Di Nicolantonio, Gianluigi De Renzi, Salvatore Caponnetto, Michela De Meo, Giuseppe Giannini, Daniele Santini, Enrico Cortesi, Paola Gazzaniga
Summary: This study investigated the clinical and genomic features associated with RAS mutation clearance in RAS mutant mCRC patients who converted to RAS wild-type. The most commonly detected actionable mutations in neo-RAS wild-type were PIK3CA. Clearance of RAS mutations in ctDNA was associated with long-term improvement of overall survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, Chiara Carlotta Pircher, Paolo Manca, Francesca Bergamo, Mirella Giordano, Caterina Sposetti, Aldo Montagna, Guglielmo Vetere, Luca Zambelli, Cosimo Rasola, Alessandra Boccaccino, Filippo Pagani, Margherita Ambrosini, Marco Massafra, Gabriella Fontanini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio
Summary: This study identified rare genomic alterations beyond RAS and BRAFV600E mutations that drive primary resistance to anti-EGFR therapy in metastatic colorectal cancer, highlighting the need for further investigation to maximize the benefit of EGFR blockade strategies.
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Eric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, Josep Tabernero, Lillian L. Siu, Michel Ducreux, Salvatore Siena, Elena Elez, Stefan Kasper, Thomas Zander, Neeltje Steeghs, Danielle Murphy, Michelle Edwards, Zev A. Wainberg
Summary: This study evaluated the combination of MEK1/2 inhibitor binimetinib and EGFR inhibitor panitumumab in patients with RAS-mutant or BRAF wild type/RAS wild-type metastatic colorectal cancer. The results showed limited clinical activity and substantial toxicity of the combination therapy in these patients.
Article
Oncology
Joeri A. J. Douma, Sonja Zweegman, Mieke Alberts, Sandy Kruyswijk, Niels C. W. J. van de Donk, Myra van Linde, Laurien M. Buffart, Henk M. W. Verheul
Summary: Objective smartphone measurements of physical activity and fitness are associated with early trial discontinuation, with high positive predictive values. Optimal cutoff values need to be externally validated in clinical practice.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Biochemistry & Molecular Biology
Maudy Walraven, Siamack Sabrkhany, Jaco C. Knol, Henk Dekker, Inge de Reus, Sander R. Piersma, Thang Pham, Arjan W. Griffioen, Henk J. Broxterman, Mirjam Oude Egbrink, Henk M. W. Verheul, Connie R. Jimenez
Summary: Platelets are potential sources of cancer biomarkers, with the proteome being affected in cancer patients. Additionally, anticancer treatment significantly alters the platelet proteome, as observed in a small group of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Bart Geboers, Florentine E. F. Timmer, Alette H. Ruarus, Johanna E. E. Pouw, Evelien A. C. Schouten, Joyce Bakker, Robbert S. Puijk, Sanne Nieuwenhuizen, Madelon Dijkstra, M. Petrousjka van den Tol, Jan J. J. de Vries, Daniela E. Oprea-Lager, C. Menke-van der Houven van Oordt, Hans J. van der Vliet, Johanna W. Wilmink, Hester J. Scheffer, Tanja D. de Gruijl, Martijn R. Meijerink
Summary: IRE is a novel technique that induces cell death through high-voltage electrical pulses applied around the tumor, which may reduce immune suppression and promote expansion of tumor-specific T cells. Combining IRE with immunotherapeutic drugs has the potential to generate a durable antitumor response.
Article
Oncology
Julia Femel, Luuk van Hooren, Melanie Herre, Jessica Cedervall, Falk Saupe, Elisabeth J. M. Huijbers, Danielle R. J. Verboogen, Matthias Reichel, Victor L. Thijssen, Arjan W. Griffioen, Lars Hellman, Anna Dimberg, Anna-Karin Olsson
Summary: Galectin-1 (Gal1) is a glycan-binding protein that promotes tumor progression through various mechanisms. Vaccination against Gal1 can generate high anti-Gal1 antibody levels and significantly impairs the growth of Gal1-expressing melanomas in mice. This is associated with improved tumor vasculature perfusion and increased infiltration of macrophages and cytotoxic T cells. Gal1 vaccination is a promising approach to enhance immunotherapeutic strategies for cancer therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Jeanet F. Karchoud, Anja J. Th C. M. de Kruif, Femke Lamers, Myra E. van Linde, Joyce M. Van Dodewaard-de Jong, Annemarie M. J. Braamse, Mirjam A. G. Sprangers, Aartjan T. F. Beekman, Henk M. W. Verheul, Joost Dekker
Summary: This study explores the indicators and strategies used by oncologists and nurses to determine the need for professional mental health care in cancer patients. The findings suggest that oncologists and nurses consider multiple factors, including the patient's emotional well-being and specific indicators of emotional problems, when making the decision to refer patients for professional mental health care.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Oncology
Mandy Gruijs, Rens Braster, Marije B. Overdijk, Tessa Hellingman, Sandra Verploegen, Rianne Korthouwer, Berend J. van der Wilk, Paul W. H. I. Parren, Hans J. van der Vliet, Marijn Boegels, Marjolein van Egmond
Summary: This study found that the use of low dose anti-EGFR mAbs prior to surgery in colorectal cancer patients can eliminate circulating tumor cells (CTCs) without interfering with wound healing, and may reduce the risk of liver metastasis, thus significantly improving long-term patient outcomes.
JOURNAL OF ONCOLOGY
(2022)
Correction
Oncology
Julia Femel, Luuk van Hooren, Melanie Herre, Jessica Cedervall, Falk Saupe, Elisabeth J. M. Huijbers, Danielle R. J. Verboogen, Matthias Reichel, Victor L. Thijssen, Arjan W. Griffioen, Lars Hellman, Anna Dimberg, Anna-Karin Olsson
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Surgery
J. K. de Bakker, L. L. Meijer, B. M. Zonderhuis, H. J. van der Vliet, F. Daams, N. C. T. van Grieken, B. Lissenberg-Witte, G. Kazemier
Summary: This study investigated the benefit of adjuvant chemotherapy for patients with resectable duodenal adenocarcinoma. The results showed no statistically significant survival benefit for adjuvant chemotherapy after curative resection in stages II and III patients. Future studies with specified treatment regimens and thorough stratification for prognostic factors are needed to determine the role of adjuvant therapy more definitively.
ACTA CHIRURGICA BELGICA
(2023)
Review
Immunology
Jose Saura-Esteller, Milon De Jong, Lisa A. King, Erik Ensing, Benjamin Winograd, Tanja D. De Gruijl, Paul W. H. I. Parren, Hans J. Van Der Vliet
Summary: Gamma delta T-cells can recognize and kill transformed cells independently of HLA-antigen presentation, making them a promising effector cell compartment for cancer immunotherapy. Current research is focused on the V delta 1 and V delta 2 T-cell subtypes, with V delta 1 enriched in tissues and V delta 2 enriched in circulation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Medicinal
I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. Hupsel, J. F. van den Nieuwendijk, I Bahce, M. Yaqub, N. H. Hendrikse
Summary: The developed physiological pharmacokinetic (PBPK) models accurately predicted the image quality and contrast of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer. These models provide the potential for predicting the image quality of new tracers in the future.
Article
Biochemistry & Molecular Biology
Lionel Mendes Dias, Mark J. de Keijzer, Daniel Ernst, Farangis Sharifi, Daniel J. de Klerk, Tony G. Kleijn, Emilie Desclos, Jakub A. Kochan, Lianne R. de Haan, Leonardo P. Franchi, Albert C. van Wijk, Enzo M. Scutigliani, Marcel H. Fens, Arjan D. Barendrecht, Jose E. B. Cavaco, Xuan Huang, Ying Xu, Weiwei Pan, Marjo J. den Broeder, Jan Bogerd, Rudiger W. Schulz, Kitty C. Castricum, Victor L. Thijssen, Shuqun Cheng, Baoyue Ding, Przemek M. Krawczyk, Michal Heger
Summary: The study developed a comprehensive tumor targeting and photosensitizer delivery platform. It was found that photodynamically active PSs effectively photosensitized cancer cells and non-cancerous cells without notable systemic toxicity. ZnPC and AlPC delivered by ITLs demonstrated strong tumor-killing capacity in human breast cancer xenografts.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lucia Sanjurjo, Esmee C. Broekhuizen, Rory R. Koenen, Victor L. J. L. Thijssen
Summary: Galectins, a family of glycan-binding proteins, play a role in shaping the immune microenvironment by directly affecting immune cell activity and survival, as well as indirectly affecting immune response through binding to cytokines. Galectin-cytokine heterodimers, known as galectokines, add complexity to immune homeostasis regulation. This article summarizes current knowledge on galectokine formation and function, describes mechanisms by which galectokines shape the immune microenvironment, and discusses outstanding questions and challenges for future research on the role of galectokines in immunomodulation.
Review
Oncology
Nina Lamers-Kok, Denise Panella, Anna-Maria Georgoudaki, Haiping Liu, Didem Ozkazanc, Lucia Kucerova, Adil Doganay Duru, Jan Spanholtz, Monica Raimo
Summary: This review summarizes the clinical status of allogeneic NK cell-based therapies for hematological and solid tumors, discusses different cell sources, engineering methods, and combination therapies. It also reviews regulatory challenges and the competitive landscape, providing a comprehensive overview.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Tesfay M. Godefa, Sarah Derks, Victor L. J. L. Thijssen
Summary: Esophageal cancer is a disease with poor overall survival. Galectins, a family of glycan-binding proteins, have been linked to tumor angiogenesis and immunosuppression and identified as diagnostic and prognostic markers in several cancer types. However, their role in esophageal cancer is still poorly understood. This literature review summarizes the expression and potential functions of galectins in esophageal cancer and highlights the gaps in current knowledge. Further research is needed to better understand the diagnostic, prognostic, and predictive value of galectins in esophageal cancer and their functional role in tumor progression.
Article
Oncology
Charlotte Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O. van der Woude, Ron A. A. Mathot, Marije Slingerland, Judith de Vos-Geelen, Massimo Zucchetti, Cristina Matteo, Erik van Dijk, Bauke Ylstra, Victor Thijssen, Sarah Derks, Tesfay Godefa, Willemieke Dijksterhuis, Gerben E. Breimer, Otto M. van Delden, Rob H. A. Verhoeven, Sybren L. Meijer, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven
Summary: The study evaluated the tolerability and efficacy of regorafenib and paclitaxel combination therapy in patients with advanced esophagogastric cancer refractory to first-line treatment. The results showed promising potential of this combination therapy in improving patient survival rates, while identifying potential negative predictive biomarkers for treatment response.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)